vs
Side-by-side financial comparison of NovoCure Ltd (NVCR) and SOLAREDGE TECHNOLOGIES, INC. (SEDG). Click either name above to swap in a different company.
SOLAREDGE TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($335.4M vs $174.3M, roughly 1.9× NovoCure Ltd). NovoCure Ltd runs the higher net margin — -14.1% vs -39.4%, a 25.3% gap on every dollar of revenue. On growth, SOLAREDGE TECHNOLOGIES, INC. posted the faster year-over-year revenue change (70.9% vs 8.1%). SOLAREDGE TECHNOLOGIES, INC. produced more free cash flow last quarter ($43.3M vs $-22.9M). Over the past eight quarters, SOLAREDGE TECHNOLOGIES, INC.'s revenue compounded faster (28.1% CAGR vs 12.2%).
NovoCure Ltd is a global oncology company that develops and commercializes innovative Tumor Treating Fields (TTFields) therapy, a non-invasive wearable treatment using low-intensity electric fields to disrupt cancer cell division. Its approved therapies target glioblastoma, malignant mesothelioma and non-small cell lung cancer, serving patients across North America, Europe and Asia Pacific.
SolarEdge Technologies, Inc. is an Israeli company that developed a DC optimized inverter system.
NVCR vs SEDG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $174.3M | $335.4M |
| Net Profit | $-24.5M | $-132.1M |
| Gross Margin | 75.8% | 22.2% |
| Operating Margin | -23.2% | -14.4% |
| Net Margin | -14.1% | -39.4% |
| Revenue YoY | 8.1% | 70.9% |
| Net Profit YoY | 62.8% | 54.0% |
| EPS (diluted) | $-0.22 | $-2.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $174.3M | $335.4M | ||
| Q3 25 | $167.2M | $340.2M | ||
| Q2 25 | $158.8M | $289.4M | ||
| Q1 25 | $155.0M | $219.5M | ||
| Q4 24 | $161.3M | $196.2M | ||
| Q3 24 | $155.1M | $235.4M | ||
| Q2 24 | $150.4M | $265.4M | ||
| Q1 24 | $138.5M | $204.4M |
| Q4 25 | $-24.5M | $-132.1M | ||
| Q3 25 | $-37.3M | $-50.1M | ||
| Q2 25 | $-40.1M | $-124.7M | ||
| Q1 25 | $-34.3M | $-98.5M | ||
| Q4 24 | $-65.9M | $-287.4M | ||
| Q3 24 | $-30.6M | $-1.2B | ||
| Q2 24 | $-33.4M | $-130.8M | ||
| Q1 24 | $-38.8M | $-157.3M |
| Q4 25 | 75.8% | 22.2% | ||
| Q3 25 | 73.2% | 21.2% | ||
| Q2 25 | 73.9% | 11.1% | ||
| Q1 25 | 75.1% | 8.0% | ||
| Q4 24 | 79.2% | -57.2% | ||
| Q3 24 | 77.2% | -309.1% | ||
| Q2 24 | 77.0% | -4.1% | ||
| Q1 24 | 75.7% | -12.8% |
| Q4 25 | -23.2% | -14.4% | ||
| Q3 25 | -21.5% | -10.3% | ||
| Q2 25 | -24.9% | -39.9% | ||
| Q1 25 | -24.4% | -46.8% | ||
| Q4 24 | -39.3% | -134.4% | ||
| Q3 24 | -20.7% | -471.8% | ||
| Q2 24 | -22.3% | -60.4% | ||
| Q1 24 | -30.0% | -85.0% |
| Q4 25 | -14.1% | -39.4% | ||
| Q3 25 | -22.3% | -14.7% | ||
| Q2 25 | -25.3% | -43.1% | ||
| Q1 25 | -22.1% | -44.9% | ||
| Q4 24 | -40.9% | -146.5% | ||
| Q3 24 | -19.7% | -522.8% | ||
| Q2 24 | -22.2% | -49.3% | ||
| Q1 24 | -28.0% | -77.0% |
| Q4 25 | $-0.22 | $-2.21 | ||
| Q3 25 | $-0.33 | $-0.84 | ||
| Q2 25 | $-0.36 | $-2.13 | ||
| Q1 25 | $-0.31 | $-1.70 | ||
| Q4 24 | $-0.61 | $-5.00 | ||
| Q3 24 | $-0.28 | $-21.58 | ||
| Q2 24 | $-0.31 | $-2.31 | ||
| Q1 24 | $-0.36 | $-2.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $93.5M | $493.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $340.5M | $427.5M |
| Total Assets | $804.3M | $2.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.5M | $493.2M | ||
| Q3 25 | $342.1M | $498.6M | ||
| Q2 25 | $149.6M | $758.0M | ||
| Q1 25 | $127.3M | $651.6M | ||
| Q4 24 | $163.8M | $585.9M | ||
| Q3 24 | $185.4M | $678.8M | ||
| Q2 24 | $164.8M | $689.8M | ||
| Q1 24 | $453.8M | $680.6M |
| Q4 25 | $340.5M | $427.5M | ||
| Q3 25 | $341.3M | $479.8M | ||
| Q2 25 | $349.4M | $513.2M | ||
| Q1 25 | $362.0M | $594.2M | ||
| Q4 24 | $360.2M | $658.3M | ||
| Q3 24 | $360.8M | $930.9M | ||
| Q2 24 | $361.8M | $2.1B | ||
| Q1 24 | $359.4M | $2.2B |
| Q4 25 | $804.3M | $2.2B | ||
| Q3 25 | $1.4B | $2.2B | ||
| Q2 25 | $1.2B | $2.5B | ||
| Q1 25 | $1.2B | $2.5B | ||
| Q4 24 | $1.2B | $2.6B | ||
| Q3 24 | $1.2B | $2.8B | ||
| Q2 24 | $1.2B | $3.9B | ||
| Q1 24 | $1.1B | $4.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.0M | $52.6M |
| Free Cash FlowOCF − Capex | $-22.9M | $43.3M |
| FCF MarginFCF / Revenue | -13.1% | 12.9% |
| Capex IntensityCapex / Revenue | 2.8% | 2.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-75.7M | $80.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.0M | $52.6M | ||
| Q3 25 | $20.6M | $25.6M | ||
| Q2 25 | $-15.9M | $-7.8M | ||
| Q1 25 | $-35.7M | $33.8M | ||
| Q4 24 | $-3.5M | $37.8M | ||
| Q3 24 | $10.4M | $-89.3M | ||
| Q2 24 | $-1.7M | $-44.8M | ||
| Q1 24 | $-31.6M | $-217.0M |
| Q4 25 | $-22.9M | $43.3M | ||
| Q3 25 | $14.9M | $22.8M | ||
| Q2 25 | $-21.4M | $-9.1M | ||
| Q1 25 | $-46.3M | $23.7M | ||
| Q4 24 | $-12.4M | $25.5M | ||
| Q3 24 | $-307.0K | $-136.7M | ||
| Q2 24 | $-13.2M | $-67.0M | ||
| Q1 24 | $-43.4M | $-243.4M |
| Q4 25 | -13.1% | 12.9% | ||
| Q3 25 | 8.9% | 6.7% | ||
| Q2 25 | -13.5% | -3.1% | ||
| Q1 25 | -29.9% | 10.8% | ||
| Q4 24 | -7.7% | 13.0% | ||
| Q3 24 | -0.2% | -58.1% | ||
| Q2 24 | -8.8% | -25.2% | ||
| Q1 24 | -31.3% | -119.1% |
| Q4 25 | 2.8% | 2.8% | ||
| Q3 25 | 3.4% | 0.8% | ||
| Q2 25 | 3.5% | 0.4% | ||
| Q1 25 | 6.8% | 4.6% | ||
| Q4 24 | 5.5% | 6.2% | ||
| Q3 24 | 6.9% | 20.1% | ||
| Q2 24 | 7.6% | 8.4% | ||
| Q1 24 | 8.5% | 12.9% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NVCR
Segment breakdown not available.
SEDG
| Other | $197.7M | 59% |
| Europe Except Netherlands | $99.4M | 30% |
| Others | $38.2M | 11% |
